User profiles for G. Remuzzi

remuzzi g*

Istituto di Ricerche Farmacologiche Mario Negri
Verified email at marionegri.it
Cited by 377833

[HTML][HTML] COVID-19 and Italy: what next?

A Remuzzi, G Remuzzi - The lancet, 2020 - thelancet.com
… We read with interest the Health Policy piece 1 by Remuzzi and Remuzzi regarding the
COVID-19 epidemic in Italy. Italy is showing us how a developed country that has never tackled …

Pathophysiology of progressive nephropathies

G Remuzzi, T Bertani - New England Journal of Medicine, 1998 - Mass Medical Soc
In patients with renal diseases characterized by proteinuria, the initial insult to the kidney is
usually followed by a progressive decline in the glomerular filtration rate. This decline has …

[HTML][HTML] Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis

…, G Reboldi, FP Cappuccio, C Agyemang, G Remuzzi… - PloS one, 2016 - journals.plos.org
Background People of Sub Saharan Africa (SSA) and South Asians(SA) ethnic minorities
living in Europe have higher risk of stroke than native Europeans(EU). Study objective is to …

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

…, D Ranganathan, JT Rehm, DB Rein, G Remuzzi - The lancet, 2012 - thelancet.com
Background Reliable and timely information on the leading causes of death in populations,
and how these are changing, is a crucial input into health policy debates. In the Global …

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

…, M Pfeffer, B Pitt, P Poole-Wilson, G Remuzzi… - Lancet, 2003 - thelancet.com
Background The benefits of reducing blood pressure on the risks of major cardiovascular
disease are well established, but uncertainty remains about the comparative effects of different …

[HTML][HTML] Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

…, AW McMahon, HH Parving, G Remuzzi… - … England Journal of …, 2009 - Mass Medical Soc
Background Statins reduce the incidence of cardiovascular events in patients at high
cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis …

[HTML][HTML] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

…, WE Mitch, HH Parving, G Remuzzi… - New England journal …, 2001 - Mass Medical Soc
… (measured in milligrams per liter) to urinary creatinine (measured in grams per liter) from
a first morning specimen of at least 300 (or a rate of urinary protein excretion of at least 0.5 g

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010

…, F Pourmalek, M Prince, JT Rehm, G Remuzzi… - The Lancet, 2012 - thelancet.com
Background Measurement of the global burden of disease with disability-adjusted life-years
(DALYs) requires disability weights that quantify health losses for all non-fatal …

[HTML][HTML] The contribution of chronic kidney disease to the global burden of major noncommunicable diseases

WG Couser, G Remuzzi, S Mendis, M Tonelli - Kidney international, 2011 - Elsevier
Noncommunicable diseases (NCDs) are the most common causes of premature death and
morbidity and have a major impact on health-care costs, productivity, and growth. …

[HTML][HTML] A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

…, P Parfrey, HH Parving, G Remuzzi… - … England Journal of …, 2009 - Mass Medical Soc
… hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with
rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary …